After excluding IDH1 R132H mutant gliomas from the analysis, the specificity increased to 41.5% for EGFR, 53.2% for MEOX2, 50.7% for SOX11 and 57.3% for INSM1. This evidence concerns the gene IDH1 and central nervous system cancer.